Independent review of trial event assessments by adjudication experts.
Proven expertise in delivering high-quality imaging data at a global scale.
With strengths in instrument engineering, signal processing, and pharmaceutical R&D, Perceptive Discovery consistently delivers successful imaging study designs and executions.
Effective RTSM, built on 30 years of experience, and connected to an ecosystem which includes eConsent and eCOA.
Highly established imaging centers for first-in-human and multicenter trials.
900+ agents radiolabeled and counting.
Supporting both malignant and non-malignant indications.
Experts in Alzheimer’s Disease, Parkinson’s Disease imaging and more.
Supporting over 85% of radiopharmaceutical companies.
Optimize preclinical and clinical trials in other areas and drug classifications.
Therapeutic and technical expertise in imaging modalities, protocol design, and acquisition.
Oncology imaging, RTSM, and clinical adjudication services.
Tackling unique rare disease trial supply, imaging and adjudication challenges.
Body composition imaging expertise you can rely on.
We are here to serve science.
From discovery, through early to late-phase clinical development, to regulatory approval and post-market, you can count on Perceptive to be dependable, diligent, and driven in everything we do.
Perceptive Discovery bridges preclinical insights to early clinical success, ensuring rigorous scientific analysis and high-quality data to support innovation.
Providing the right-fit randomization & trial supply management solution for your trials, delivered by experts.
The right people, experience, and technology to drive clinical trial imaging success.
Synonyms: Astatine-211, ²¹¹At, At-211, alpha emitter, targeted alpha therapy (TAT), alpha radiotherapy, radiolabeled small molecules, radiolabeled peptides, radiopharmaceutical research, alpha particle isotope, radioligand therapy
Astatine-211 (²¹¹At) is an alpha-emitting radioisotope with unique potential in targeted alpha therapy (TAT) for cancer and other diseases requiring high-precision cytotoxicity. Its short-range, high-linear energy transfer (LET) alpha particles enable the selective destruction of malignant cells while minimizing damage to surrounding healthy tissue. In preclinical and translational research, ²¹¹At is often conjugated to small molecules, peptides, or other targeting vectors to evaluate therapeutic efficacy and dosimetry in novel drug candidates.
Radiation Type: Alpha emitter (energy ~5.87 MeV) Half-life: ~7.2 hours – suitable for targeted delivery and rapid clearance
Learn more about our preclinical radiopharmaceutical services
Reach out today and one of our solution experts will be in touch to learn about your specific needs.
"*" indicates required fields
Δ
